TY - JOUR
T1 - Cardiac diseases following childhood cancer treatment
T2 - Cohort study
AU - Haddy, Nadia
AU - Diallo, Stéphanie
AU - El-Fayech, Chiraz
AU - Schwartz, Boris
AU - Pein, François
AU - Hawkins, Mike
AU - Veres, Cristina
AU - Oberlin, Odile
AU - Guibout, Catherine
AU - Pacquement, Hélène
AU - Munzer, Martine
AU - N'Guyen, Tan Dat
AU - Bondiau, Pierre Yves
AU - Berchery, Delphine
AU - Laprie, Anne
AU - Scarabin, Pierre Yves
AU - Jouven, Xavier
AU - Bridier, André
AU - Koscielny, Serge
AU - Deutsch, Eric
AU - Diallo, Ibrahima
AU - De Vathaire, Florent
N1 - Publisher Copyright:
© 2015 American Heart Association, Inc.
PY - 2016/1/5
Y1 - 2016/1/5
N2 - Background - Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD. Methods and Results - The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated. There were 347 CDs in 234 patients, 156 of them were rated grade ≥3. Cox and Poisson regression models were used. The cumulative incidence of any type of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5-12.7) and 7·4% (95% CI, 6.2-8.9) when only the CDs of grade ≥3 were considered. In comparison with patients who received no anthracycline and either no radiotherapy or an HRD<0·1Gy, the risk was multiplied by 18·4 (95% CI, 7.1-48.0) in patients who had received anthracycline and no radiotherapy or a HRD <0.1Gy, by 60.4 (95% CI, 22.4-163.0) in those who had received no anthracycline and an HRD≥30Gy, and 61.5 (95% CI, 19.6-192.8) in those who had received both anthracycline and an HRD≥30Gy. Conclusions - Survivors of childhood cancers treated with radiotherapy and anthracycline run a high dose-dependent risk of developing CD. CDs develop earlier in patients treated with anthracycline than in those treated without it.
AB - Background - Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD. Methods and Results - The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated. There were 347 CDs in 234 patients, 156 of them were rated grade ≥3. Cox and Poisson regression models were used. The cumulative incidence of any type of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5-12.7) and 7·4% (95% CI, 6.2-8.9) when only the CDs of grade ≥3 were considered. In comparison with patients who received no anthracycline and either no radiotherapy or an HRD<0·1Gy, the risk was multiplied by 18·4 (95% CI, 7.1-48.0) in patients who had received anthracycline and no radiotherapy or a HRD <0.1Gy, by 60.4 (95% CI, 22.4-163.0) in those who had received no anthracycline and an HRD≥30Gy, and 61.5 (95% CI, 19.6-192.8) in those who had received both anthracycline and an HRD≥30Gy. Conclusions - Survivors of childhood cancers treated with radiotherapy and anthracycline run a high dose-dependent risk of developing CD. CDs develop earlier in patients treated with anthracycline than in those treated without it.
KW - anthracycline
KW - childhood cancer
KW - cohort studies
KW - heart diseases
KW - radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=84953839793&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.115.016686
DO - 10.1161/CIRCULATIONAHA.115.016686
M3 - Article
C2 - 26487757
AN - SCOPUS:84953839793
SN - 0009-7322
VL - 133
SP - 31
EP - 38
JO - Circulation
JF - Circulation
IS - 1
ER -